JP2023500437A5 - - Google Patents
Info
- Publication number
- JP2023500437A5 JP2023500437A5 JP2022523102A JP2022523102A JP2023500437A5 JP 2023500437 A5 JP2023500437 A5 JP 2023500437A5 JP 2022523102 A JP2022523102 A JP 2022523102A JP 2022523102 A JP2022523102 A JP 2022523102A JP 2023500437 A5 JP2023500437 A5 JP 2023500437A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- group
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024018866A JP7702004B2 (ja) | 2019-10-16 | 2024-02-09 | ヒトインテグリンα4β7の阻害 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916062P | 2019-10-16 | 2019-10-16 | |
| US62/916,062 | 2019-10-16 | ||
| PCT/US2020/055986 WO2021076890A1 (en) | 2019-10-16 | 2020-10-16 | INHIBITING HUMAN INTEGRIN α4β7 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024018866A Division JP7702004B2 (ja) | 2019-10-16 | 2024-02-09 | ヒトインテグリンα4β7の阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500437A JP2023500437A (ja) | 2023-01-06 |
| JP2023500437A5 true JP2023500437A5 (cg-RX-API-DMAC7.html) | 2023-04-03 |
| JP7437495B2 JP7437495B2 (ja) | 2024-02-22 |
Family
ID=73198501
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509595A Active JP7437490B2 (ja) | 2019-10-16 | 2020-10-16 | ヒトインテグリン(アルファ-4)(ベータ-7)の阻害 |
| JP2022523102A Active JP7437495B2 (ja) | 2019-10-16 | 2020-10-16 | ヒトインテグリンα4β7の阻害 |
| JP2021576053A Active JP7209116B2 (ja) | 2019-10-16 | 2021-10-15 | ヒトインテグリンα4β7の阻害 |
| JP2023000761A Active JP7500785B2 (ja) | 2019-10-16 | 2023-01-06 | ヒトインテグリンα4β7の阻害 |
| JP2024018866A Active JP7702004B2 (ja) | 2019-10-16 | 2024-02-09 | ヒトインテグリンα4β7の阻害 |
| JP2024018765A Active JP7717202B2 (ja) | 2019-10-16 | 2024-02-09 | ヒトインテグリン(アルファ-4)(ベータ-7)の阻害 |
| JP2024091304A Active JP7869261B2 (ja) | 2019-10-16 | 2024-06-05 | ヒトインテグリンα4β7の阻害 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509595A Active JP7437490B2 (ja) | 2019-10-16 | 2020-10-16 | ヒトインテグリン(アルファ-4)(ベータ-7)の阻害 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576053A Active JP7209116B2 (ja) | 2019-10-16 | 2021-10-15 | ヒトインテグリンα4β7の阻害 |
| JP2023000761A Active JP7500785B2 (ja) | 2019-10-16 | 2023-01-06 | ヒトインテグリンα4β7の阻害 |
| JP2024018866A Active JP7702004B2 (ja) | 2019-10-16 | 2024-02-09 | ヒトインテグリンα4β7の阻害 |
| JP2024018765A Active JP7717202B2 (ja) | 2019-10-16 | 2024-02-09 | ヒトインテグリン(アルファ-4)(ベータ-7)の阻害 |
| JP2024091304A Active JP7869261B2 (ja) | 2019-10-16 | 2024-06-05 | ヒトインテグリンα4β7の阻害 |
Country Status (37)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202528300A (zh) | 2018-04-12 | 2025-07-16 | 美商莫菲克醫療股份有限公司 | 人類整合素α4β7拮抗劑 |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| BR112021022659A2 (pt) | 2019-05-15 | 2022-03-29 | Chemocentryx Inc | Compostos triarílicos para o tratamento de doenças pd-l1 |
| AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| BR112022007284A2 (pt) * | 2019-10-16 | 2022-07-05 | Morphic Therapeutic Inc | Inibição de integrina humana alpha-4 beta-7 |
| AU2020368392B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| ES3068390T3 (en) | 2019-10-16 | 2026-05-29 | Chemocentryx Inc | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| US20250195485A1 (en) * | 2021-12-27 | 2025-06-19 | Xizang Haisco Pharmaceutical Co., Ltd. | Propionic acid derivative and medical use thereof |
| EP4585587A1 (en) | 2022-09-09 | 2025-07-16 | Xizang Haisco Pharmaceutical Co., Ltd. | Propionic acid derivative and use thereof in medicine |
| CN120500479A (zh) | 2022-12-22 | 2025-08-15 | 新特拉有限公司 | α4β7整联蛋白拮抗剂及其用途 |
| CN120957974A (zh) * | 2023-02-21 | 2025-11-14 | 希四克斯探索有限公司 | 大环α4β7整合素抑制剂 |
| WO2024249328A2 (en) | 2023-05-26 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
| WO2025026955A1 (en) * | 2023-07-28 | 2025-02-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| AU2024317579A1 (en) | 2023-07-28 | 2026-02-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof |
| WO2025176107A1 (zh) * | 2024-02-20 | 2025-08-28 | 西藏海思科制药有限公司 | 一种吡啶酮衍生物及其在医药上的应用 |
| CN118702712B (zh) * | 2024-07-04 | 2025-11-11 | 安徽普利药业有限公司 | 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法 |
| WO2026018016A1 (en) * | 2024-07-19 | 2026-01-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2026018017A1 (en) * | 2024-07-19 | 2026-01-22 | C4X Discovery Limited | Therapeutic compounds |
| CN119504796B (zh) * | 2024-11-20 | 2026-03-10 | 南通大学附属医院 | 一种具有抗肿瘤活性的化合物及其应用 |
| WO2026138844A1 (zh) * | 2024-12-24 | 2026-07-02 | 湖北生物医药产业技术研究院有限公司 | 酰胺类化合物及其作为整合素α4β7拮抗剂的用途 |
| WO2026156089A1 (en) | 2025-01-17 | 2026-07-23 | Eli Lilly And Company | Small molecule alpha4beta7 integrin inhibitor for use in the treatment of inflammatory bowel disease |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69425431T2 (de) | 1993-03-31 | 2001-02-08 | G.D. Searle & Co., Chicago | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| DE19622489A1 (de) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters |
| CA2268381A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| WO1998016524A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| ES2221227T3 (es) | 1997-11-24 | 2004-12-16 | MERCK & CO., INC. | Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular. |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| WO2000000481A1 (en) | 1998-06-29 | 2000-01-06 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
| WO2000006169A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| SK288186B6 (sk) * | 1999-05-07 | 2014-05-06 | Encysive Pharmaceuticals, Inc. | Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| EP1214292B1 (en) | 1999-09-24 | 2007-06-13 | Genentech, Inc. | Tyrosine derivatives |
| DE10041423A1 (de) | 2000-08-23 | 2002-03-07 | Merck Patent Gmbh | Biphenylderivate |
| BR0113671A (pt) * | 2000-08-30 | 2004-01-06 | Pharmacia Corp | Antagonistas de integrina alfa v beta 3 gem-substituìda |
| DE10111876A1 (de) | 2001-03-10 | 2002-09-19 | Aventis Pharma Gmbh | Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe |
| DE10154280A1 (de) | 2001-11-05 | 2003-05-15 | Wilex Ag | Antagonisten für alpha¶4¶-Integrine |
| KR20040105740A (ko) | 2002-02-25 | 2004-12-16 | 엘란 파마슈티칼스, 인크. | 염증 치료제의 투여 방법 |
| ES2377979T3 (es) | 2004-09-03 | 2012-04-03 | Genentech, Inc. | Antagonistas anti-beta7 humanizados y utilizaciones para los mismos |
| ES2387317T3 (es) | 2005-03-03 | 2012-09-20 | Seedlings Life Science Ventures, Llc. | Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体 |
| CA2610800A1 (en) | 2005-06-09 | 2006-12-14 | Ucb Pharma, S.A. | 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| US20100272680A1 (en) | 2009-02-09 | 2010-10-28 | Subramanian Baskaran | Piperidinyl Cyclic Amido Antiviral Agents |
| MX2013011130A (es) | 2011-03-31 | 2013-10-30 | Genentech Inc | Metodos de administracion de antagonistas de integrina beta7. |
| KR101850591B1 (ko) | 2012-10-05 | 2018-04-19 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
| JP7054990B2 (ja) | 2014-03-27 | 2022-04-15 | ジェネンテック, インコーポレイテッド | 炎症性腸疾患の診断及び治療のための方法 |
| CN105658641B (zh) | 2014-07-25 | 2018-04-17 | 江苏恒瑞医药股份有限公司 | 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用 |
| EP3224280A1 (en) * | 2014-11-26 | 2017-10-04 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| EP3978530A1 (en) | 2015-02-26 | 2022-04-06 | F. Hoffmann-La Roche AG | Integrin beta7 antagonists and methods of treating crohn's disease |
| EP4159727B1 (en) * | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| TW202528300A (zh) * | 2018-04-12 | 2025-07-16 | 美商莫菲克醫療股份有限公司 | 人類整合素α4β7拮抗劑 |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| WO2020092401A1 (en) * | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| ES2987796T3 (es) * | 2018-10-30 | 2024-11-18 | Gilead Sciences Inc | Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias |
| BR112022007284A2 (pt) * | 2019-10-16 | 2022-07-05 | Morphic Therapeutic Inc | Inibição de integrina humana alpha-4 beta-7 |
-
2020
- 2020-10-16 BR BR112022007284A patent/BR112022007284A2/pt unknown
- 2020-10-16 WO PCT/US2020/055986 patent/WO2021076890A1/en not_active Ceased
- 2020-10-16 UA UAA202201185A patent/UA130059C2/uk unknown
- 2020-10-16 RS RS20250645A patent/RS66976B1/sr unknown
- 2020-10-16 MA MA57399A patent/MA57399B1/fr unknown
- 2020-10-16 EP EP20875989.4A patent/EP4045039B1/en active Active
- 2020-10-16 WO PCT/US2020/056001 patent/WO2021076902A1/en not_active Ceased
- 2020-10-16 MD MDE20220933T patent/MD4045039T2/ro unknown
- 2020-10-16 TW TW109136036A patent/TWI775182B/zh active
- 2020-10-16 KR KR1020227015040A patent/KR20220102669A/ko not_active Ceased
- 2020-10-16 CN CN202411308053.XA patent/CN119192137A/zh active Pending
- 2020-10-16 PY PY202002065718A patent/PY2065718A/es unknown
- 2020-10-16 DK DK20875989.4T patent/DK4045039T3/da active
- 2020-10-16 UY UY0001038926A patent/UY38926A/es unknown
- 2020-10-16 PT PT208759894T patent/PT4045039T/pt unknown
- 2020-10-16 CN CN202080088450.4A patent/CN115087444B/zh active Active
- 2020-10-16 CR CR20220205A patent/CR20220205A/es unknown
- 2020-10-16 EP EP25157767.2A patent/EP4559525B1/en active Active
- 2020-10-16 JP JP2022509595A patent/JP7437490B2/ja active Active
- 2020-10-16 US US17/769,003 patent/US20240174632A1/en active Pending
- 2020-10-16 PH PH1/2022/550886A patent/PH12022550886A1/en unknown
- 2020-10-16 JP JP2022523102A patent/JP7437495B2/ja active Active
- 2020-10-16 HR HRP20250749TT patent/HRP20250749T1/hr unknown
- 2020-10-16 ES ES20875989T patent/ES3035561T3/es active Active
- 2020-10-16 MX MX2022004406A patent/MX2022004406A/es unknown
- 2020-10-16 CA CA3154269A patent/CA3154269A1/en active Pending
- 2020-10-16 PE PE2022000633A patent/PE20221829A1/es unknown
- 2020-10-16 LT LTEPPCT/US2020/055986T patent/LT4045039T/lt unknown
- 2020-10-16 TW TW113132607A patent/TWI900200B/zh active
- 2020-10-16 CU CU2022000027A patent/CU20220027A7/es unknown
- 2020-10-16 IL IL319053A patent/IL319053A/en unknown
- 2020-10-16 SI SI202030622T patent/SI4045039T1/sl unknown
- 2020-10-16 TW TW111127993A patent/TWI802477B/zh active
- 2020-10-16 US US17/072,797 patent/US11104661B1/en active Active
- 2020-10-16 FI FIEP20875989.4T patent/FI4045039T3/fi active
- 2020-10-16 AU AU2020366435A patent/AU2020366435B2/en active Active
- 2020-10-16 PL PL20875989.4T patent/PL4045039T3/pl unknown
- 2020-10-16 HU HUE20875989A patent/HUE071814T2/hu unknown
- 2020-10-16 TW TW112116098A patent/TWI857592B/zh active
- 2020-10-16 AR ARP200102870A patent/AR120244A1/es unknown
-
2021
- 2021-07-16 US US17/378,282 patent/US11370773B1/en active Active
- 2021-10-15 WO PCT/US2021/055196 patent/WO2022081983A1/en not_active Ceased
- 2021-10-15 TW TW111149835A patent/TWI840047B/zh active
- 2021-10-15 CN CN202610307420.7A patent/CN122251398A/zh active Pending
- 2021-10-15 AU AU2021361031A patent/AU2021361031A1/en active Pending
- 2021-10-15 KR KR1020237015039A patent/KR20230088376A/ko active Pending
- 2021-10-15 TW TW113110859A patent/TWI888065B/zh active
- 2021-10-15 JP JP2021576053A patent/JP7209116B2/ja active Active
- 2021-10-15 EP EP21881178.4A patent/EP4228634A4/en active Pending
- 2021-10-15 TW TW110138309A patent/TWI791304B/zh active
- 2021-10-15 CN CN202180083775.8A patent/CN116783161B/zh active Active
-
2022
- 2022-04-05 ZA ZA2022/03872A patent/ZA202203872B/en unknown
- 2022-04-13 DO DO2022000081A patent/DOP2022000081A/es unknown
- 2022-04-14 IL IL292296A patent/IL292296B2/en unknown
- 2022-04-14 CL CL2022000959A patent/CL2022000959A1/es unknown
- 2022-05-02 CO CONC2022/0005759A patent/CO2022005759A2/es unknown
- 2022-05-16 EC ECSENADI202238978A patent/ECSP22038978A/es unknown
-
2023
- 2023-01-06 JP JP2023000761A patent/JP7500785B2/ja active Active
- 2023-03-30 ZA ZA2023/03992A patent/ZA202303992B/en unknown
-
2024
- 2024-02-09 JP JP2024018866A patent/JP7702004B2/ja active Active
- 2024-02-09 JP JP2024018765A patent/JP7717202B2/ja active Active
- 2024-06-05 JP JP2024091304A patent/JP7869261B2/ja active Active
-
2025
- 2025-02-19 DO DO2025000034A patent/DOP2025000034A/es unknown
-
2026
- 2026-07-20 AU AU2026206251A patent/AU2026206251A1/en active Pending